journal article·2017-09-22Open access

The Effect of RANKL/OPG Balance on Reducing Implant Complications

Elizabeth Kapasa, Peter Giannoudis, Xiaodong Jia, Paul Hatton, Xuebin Yang

Abstract

Despite the phenomenal success of implants particularly in the realms of dentistry and orthopaedics, there are still challenges to overcome. The failure of implants resulting from infection, prosthetic loosening, and non-union continue to be the most notorious examples. The cascade of fracture healing and bone repair, especially with the presence of an implant, is complex because it involves a multifaceted immune response alongside the intricate process of bone formation and remodelling. Bone loss is a serious clinical problem that is frequently accompanied by chronic inflammation, illustrating that there is a convoluted relationship between inflammation and bone erosion. The effects of pro-inflammatory factors play a significant role in initiating and maintaining osteoclastogenesis that results in bone resorption by osteoclasts. This is because there is a disruption of the relative ratio between Receptor Activator of Nuclear Factor κB-Ligand (RANKL) and osteoprotegerin (OPG), which is central to modulating bone repair and remodelling. This review aims to provide a background to the bone remodelling process, the bone repair cascade post-implantation, and the associated complications. Furthermore, current clinical solutions that can influence bone formation via either internal or extrinsic mechanisms will be described. These efficacious treatments for osteolysis via targeting the RANKL/OPG ratio may be crucial to reducing the incidence of related implant failures in the future.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Metabolism and Diseases · Orthopaedic implants and arthroplasty · Bone health and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Doctoral Training Centre—Regenerative Medicine, Institute of Medical and Biological Engineering, School of Mechanical Engineering, University of Leeds, Leeds LS2 9JT, UK

Biomaterials and Tissue Engineering Group, School of Dentistry, University of Leeds, Leeds LS2 9JT, UK

Department of Trauma and Orthopaedic Surgery, School of Medicine, University of Leeds, Leeds LS2 9JT, UK

School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, UK

School of Clinical Dentistry, University of Sheffield, Sheffield S10 2TA, UK

Funding

Engineering and Physical Sciences Research Council · EC FP7/2007-2013 · Changzhou Science and Technology Bureau

References (68)

Show source-provided references
1. Bone lysis and inflammation10.1007/s00011-004-1303-z ↗
2. Clough, J. (2009). The Cleveland Clinic Guide to Arthritis, Kaplan Publishing.
3. Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years10.1093/rheumatology/kex172 ↗
4. The role of macrophages in osteolysis of total joint replacement10.1016/j.biomaterials.2004.04.035 ↗
5. Biological response to prosthetic debris10.5312/wjo.v6.i2.172 ↗
6. Inflammation and bone loss in periodontal disease10.1902/jop.2008.080233 ↗
7. Osteoimmunology: Major and costimulatory pathway expression associated with chronic inflammatory induced bone loss10.1155/2015/281287 ↗
8. Biology of RANK, RANKL, and osteoprotegerin10.1186/ar2165 ↗
9. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption10.1007/s001980070028 ↗
10. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling10.1016/j.cytogfr.2004.06.004 ↗
11. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength10.1016/j.coph.2005.06.005 ↗
12. RANK, RANKL and osteoprotegerin in bone biology and disease10.1007/s12178-009-9046-7 ↗
13. Evidence for osteocyte regulation of bone homeostasis through RANKL expression10.1038/nm.2452 ↗
14. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo10.1359/jbmr.2000.15.1.60 ↗
15. Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading10.1016/j.bone.2004.05.024 ↗
16. Bone fracture and bone fracture repair10.1007/s00198-011-1611-4 ↗
17. The modulatory effects of mesenchymal stem cells on osteoclastogenesis10.1155/2016/1908365 ↗
18. Functions of RANKL/RANK/OPG in bone modeling and remodeling10.1016/j.abb.2008.03.018 ↗
19. Osteoclast differentiation and activation10.1038/nature01658 ↗
20. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis10.1155/2013/125705 ↗
21. Osteoprotegerin ligand: A regulator of immune responses and bone physiology10.1016/S0167-5699(00)01718-7 ↗
22. RANK/RANKl: Regulators of immune responses and bone physiology10.1196/annals.1443.016 ↗
23. Current concepts of molecular aspects of bone healing10.1016/j.injury.2005.07.019 ↗
24. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis10.1177/154405910808700215 ↗
25. Expression of osteoprotegerin, receptor activator of nf-κb ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing10.1359/jbmr.2001.16.6.1004 ↗
26. The biology of fracture healing10.1016/j.injury.2011.03.031 ↗
27. Chondrocytes-specific expression of osteoprotegerin modulates osteoclast formation in metaphyseal bone10.1038/srep13667 ↗
28. Regulation of osteoclast activity in peri-implant tissues10.1016/j.biomaterials.2004.01.003 ↗
29. The osteoclastogenic molecules RANKL and rank are associated with periprosthetic osteolysis10.1302/0301-620X.83B6.0830902 ↗
30. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: Expression of receptor activator nfκb, rank ligand and osteoprotegerin10.1016/S0142-9612(03)00556-8 ↗
31. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles10.1016/j.biomaterials.2004.05.017 ↗
32. The correlation of RANK, RANKL and TNF-α expression with bone loss volume and polyethylene wear debris around hip implants10.1016/j.biomaterials.2006.05.054 ↗
33. Over-expression of receptor activator of nuclear factor-κb ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty10.1016/j.biomaterials.2009.09.017 ↗
34. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells10.1016/S0142-9612(01)00371-4 ↗
35. Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts10.1007/s11596-014-1265-5 ↗
36. Functional human t-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection10.1172/JCI10763 ↗
37. The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts10.1016/j.biomaterials.2004.01.053 ↗
38. Prostaglandin e2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro10.1210/endo.139.7.6085 ↗
39. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis10.1016/S0736-0266(02)00106-7 ↗
40. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption10.1002/jor.1100170510 ↗
41. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty10.2106/00004623-200509000-00003 ↗
42. Differential expression of rankl and osteoprotegerin in gingival crevicular fluid of patients with periodontitis10.1177/154405910408300216 ↗
43. Pressure-induced periprosthetic osteolysis: A rat model10.1002/jor.1100180322 ↗
44. Understanding peri-implant endosseous healing10.1002/j.0022-0337.2003.67.8.tb03681.x ↗
45. Microstimulation at the bone–implant interface upregulates osteoclast activation pathways10.1016/j.bone.2007.09.055 ↗
46. Biological reactions to different dental implant surface treatments
47. Surface modifications and their effects on titanium dental implants10.1155/2015/791725 ↗
48. Surface modification of biomedical and dental implants and the processes of inflammation, wound healing and bone formation10.3390/ijms11010354 ↗
49. Biomaterials for bone tissue engineering10.1016/S1369-7021(08)70086-5 ↗
50. Metal is not inert: Role of metal ions released by biocorrosion in aseptic loosening—Current concepts10.1002/jbm.a.32625 ↗
51. Bio-corrosion of stainless steel by osteoclasts—In vitro evidence10.1002/jor.20831 ↗
52. Titanium uptake, induction of RANK-L expression, and enhanced proliferation of human t-lymphocytes10.1002/jor.21013 ↗
53. Biocorrosion and uptake of titanium by human osteoclasts10.1002/jbm.a.32914 ↗
54. The role of biosilica in the osteoprotegerin/RANKL ratio in human osteoblast-like cells10.1016/j.biomaterials.2010.07.002 ↗
55. Enzymatically synthesised inorganic polymers morphogenetically active bone scaffolds: Application in regenerative medicine10.1016/B978-0-12-800177-6.00002-5 ↗
56. Mechanisms regulating increased production of osteoprotegerin by osteoblasts cultured on microstructured titanium surfaces10.1016/j.biomaterials.2009.03.047 ↗
57. Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts10.1111/j.1600-0501.2010.02033.x ↗
58. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes a potential treatment for aseptic loosening of total joint components10.2106/00004623-200107000-00012 ↗
59. Osteoblast proliferation and maturation by bisphosphonates10.1016/j.biomaterials.2003.11.024 ↗
60. Denosumab and bisphosphonates: Different mechanisms of action and effects10.1016/j.bone.2010.11.020 ↗
61. Use of bisphosphonates in orthopedic surgery
62. DeGroot, L.J., and Jameson, J.L. (2016). Bone development and remodeling. Endocrinology: Adult and Pediatric, Elsevier Health Sciences. [7th ed.].
63. The effect of a single dose of osteoprotegerin in postmenopausal women10.1359/jbmr.2001.16.2.348 ↗
64. Denosumab for the treatment of osteoporosis10.1016/j.afos.2017.01.002 ↗
65. Receptor activator of nuclear factor κb ligand and osteoprotegerin regulation of bone remodeling in health and disease10.1210/er.2007-0014 ↗
66. Osteonecrosis of the jaws induced by anti-rank ligand therapy10.1016/j.bjoms.2009.08.030 ↗
67. Denosumab-related osteonecrosis of the jaw10.14219/jada.archive.2012.0323 ↗
68. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials10.1007/s10147-013-0561-6 ↗